KA
CELG

Klingman & Associates’s Celgene Corp CELG Stock Holding History

Klingman & Associates’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-300
Closed -$31K – 371
2016
Q3 		$31K Buy
+300
New +$32.5K 0.01% 225
2015
Q3 		– Sell
-208
Closed -$24K – 472
2015
Q2 		$24K Buy
+208
New +$23.8K 0.01% 242

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Klingman & Associates's CELG Position: Q4 2016 in Review

Klingman & Associates sold out of Celgene Corp (CELG) in Q4 2016, closing a stake of 300 shares — an estimated $31K sold.

Klingman & Associates first reported a position in CELG in Q2 2015 and held it in 2 quarters. The position peaked at $31K in Q3 2016. 1,375 funds tracked by Wall St. Rank hold CELG as of Q4 2016.

  • Klingman & Associates reported no remaining Celgene Corp position as of Q4 2016 after selling out during the quarter.
  • Klingman & Associates sold 300 Celgene Corp shares in Q4 2016, an estimated $31K.
  • Klingman & Associates first reported a position in Celgene Corp in Q2 2015 and held it in 2 quarters.
  • Klingman & Associates's Celgene Corp position peaked at $31K in Q3 2016.
  • 1,375 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2016.

Based on Klingman & Associates's 13F filing for Q4 2016, filed 26 Jan 2017.